Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viatris Inc. (VTRS) EV/EBITDA

Alert me on EV/EBITDA

As of 16 October 2026, Viatris Inc. (VTRS) trades at a EV/EBITDA of 12.6×. Over the past ten years it has ranged from 6.3× (March 2023) to 22.0× (April 2015); the current reading is higher than 78% of that period. That is in line with the Drug Manufacturers Specialty & Generic industry median of 12.6× and above the Healthcare sector median of 9.2×.

EV/EBITDA, daily

Embed this chart

Annual newest first

Period EV/EBITDA Change
FY2025 9.0× (3.55%)
FY2024 9.3× 23.86%
FY2023 7.5× 10.04%
FY2022 6.9× (20.90%)
FY2021 8.7× (55.17%)
FY2020 19.3× 124.15%
FY2019 8.6× (5.73%)
FY2018 9.1× (23.39%)
FY2017 11.9× (26.25%)
FY2016 16.2× 27.39%

Quarterly newest first

Period EV/EBITDA Change
Jun 2026 11.4× 19.32%
Mar 2026 9.5× 5.99%
Dec 2025 9.0× 2.91%
Sep 2025 8.8× 3.24%
42 more quarters

Against its own ten years

Low 6.3× High 22.0×
Ten-year median 9.4×
Current reading's percentile 78

EV/EBITDA against peers

Company EV/EBITDA
ZTS Zoetis Inc. compare 10.4×
TAK Takeda Pharmaceutical Co. compare 10.8×
VTRS Viatris Inc. 12.6×
HLN Haleon PLC Sponsored ADR compare 13.3×
UTHR United Therapeutics Corporation compare 13.6×
NBIX Neurocrine Biosciences, Inc. compare 16.7×
RDY Dr. Reddy's Laboratories Ltd compare 17.0×
ELAN Elanco Animal Health Incorporated compare 19.6×
TEVA Teva Pharmaceutical Industries Ltd. compare 24.5×
Drug Manufacturers Specialty & Generic industry median 12.6×
Healthcare sector median 9.2×
Market median 11.0×

What EV/EBITDA is

Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)

The full definition of EV/EBITDA →

More on VTRS